中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

10 records (took 0.021 seconds)

    PREDICTION OF THE EFFICACY OF A MEDICAMENT ON RENAL OR CARDIOVASCULAR CLINICAL OUTCOMES
    1.
    发明申请
    PREDICTION OF THE EFFICACY OF A MEDICAMENT ON RENAL OR CARDIOVASCULAR CLINICAL OUTCOMES 审中-公开
    一种药物对肾脏或心血管临床结局的预测

    公开(公告)号：WO2013122469A3

    公开(公告)日：2013-10-10

    申请号：PCT/NL2013050098

    申请日：2013-02-18

    Applicant: UNIV GRONINGEN ,  GRONINGEN ACAD ZIEKENHUIS ,  UMC UTRECHT HOLDING BV ,  STICHTING TOP INST PHARMA

    Inventor： LAMBERS HEERSPINK HIDDO JAN ,  DE ZEEUW DICK ,  GROBBEE DIEDERICK EGBERTUS

    IPC: G06F19/00

    CPC classification number: G16H50/20

    Abstract: For obtaining a prediction of the long-term efficacy of a medicament on reducing a risk of a renal clinical outcome or a cardiovascular clinical outcome, a multivariate risk relation is determined from values (8) of a plurality of biomarkers and the occurrence in the past (11) of said clinical outcome. The biomarkers include systolic blood pressure, ratio between albumin and creatinine contents in urine, and potassium, Hb A1c, and total cholesterol contents in blood. The risk relation is applied to reference biomarker values (16, 18a) for determining a reference estimate of a risk of future occurrence of that clinical outcome (2a) and to medicament affected biomarker values after a short-term treatment period (18b) for determining a medicament affected estimate of a long-term risk of future occurrence of that clinical outcome (2b). The long-term medicament efficacy estimate (19) is determined from the reference risk estimate and the medicament affected risk estimate.

    Abstract translation: 为了获得药物对降低肾脏临床结果或心血管临床结果风险的长期功效的预测，根据多个生物标记的值（8）和过去的发生来确定多变量风险关系 （11）所述临床结果。 生物标志物包括收缩压，尿中白蛋白和肌酸酐含量之比，血液中钾，Hb A1c和总胆固醇含量。 将风险关系应用于参考生物标志值（16,18a）以确定未来发生该临床结果的风险的参考估计（2a）以及用于确定短期治疗时期（18b）之后的药物影响生物标志值以用于确定 药物影响对该临床结果未来发生的长期风险的估计（2b）。 长期药物疗效评估（19）由参考风险评估和药物影响风险评估确定。

Patent Agency Ranking